CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Orchard Therapeutics PLC - ADR is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Orchard Therapeutics PLC - ADR
245 Hammersmith Road, 3Rd Floor
Phone: +44 2033846700p:+44 2033846700 London, W6 8PW  United Kingdom
This company was Merged or Acquired on 1/24/2024.
This company ceased filing statements with the SEC on 2/5/2024.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Orchard Therapeutics plc is a gene therapy company. The Company is engaged in transforming the lives of people affected by rare diseases through the development of curative gene therapies. Its ex vivo autologous hematopoietic stem cell (HSC), gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. Its ex vivo autologous HSC gene therapy approach seeks to transform a patient’s autologous HSCs into a gene-modified cellular drug product to treat the patient’s disease. Its lead program is OTL-200 operates under the brand name Libmeldy for eligible patients with early-onset metachromatic leukodystrophy (MLD). Its programs in immunological disorders consist of two pre-clinical programs, OTL-104 for Crohn’s disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2 (NOD2-CD), and OTL-105 for hereditary angioedema (HAE).
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
6719 Offices of holding companies, not elsewhere classified
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board James A.Geraghty 68 5/1/2018 5/1/2018
President & Chief Executive Officer MarkRothera
Chief Financial Officer & Chief Business Officer Frank E.Thomas
8 additional Officers and Directors records available in full report.

Business Names
Business Name
Orchard Therapeutics (Europe) Limited
Orchard Therapeutics (France) SAS
Orchard Therapeutics (Germany) GmbH
7 additional Business Names available in full report.

General Information
Number of Employees: 166 (As of 12/31/2022)
Outstanding Shares: 227,610,439 (As of 11/9/2023)
Shareholders: 56
Stock Exchange: NASD


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024